MedTech is identified as a soft spot in J&J case.

2 reports, 2 independent Updated Aug 27

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

MedTech is identified as a soft spot in J&J case.

Who's involved

What this event is mainly about

Johnson & Johnson Medtech

Keep exploring

Part of

Medical device sales are up in the U.S., but major players like J&J are facing market headwinds due to the VBP program in China. All 1 developments

The entities involved

Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.Fri 16:46
- Zusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.Fri 04:48
Medtech
medical education facility founded in 2004 in Indianapolis, U.S
- Johnson & Johnson operates a business unit focused on surgical and orthopedic equipment.Mon 16:21
- Orthopaedics separation is expected to reshape Johnson & Johnson's MedTech segment.Mon 15:38

Related events

Johnson & Johnson joins the USMN initiative.Oct 22

Coverage

Newest first; wire copies grouped

Aug 27fool.com
Aug 17yahoo.com